化学性质:
规格 | 500μg |
CAS | 129121-73-9 |
别名 |
|
化学名 | (3S,4Z,6S,7Z,9S,10Z,12S,13Z,16Z,19Z,21S,22Z,24S,25Z,27S,28Z,30S,31Z,33S,34Z,37Z,39S,40Z,42S,43Z,45S,46Z,48S,49Z,51S,52Z,54S)-48-((1H-imidazol-5-yl)methyl)-54-amino-6-(4-aminobutyl)-3-((Z)-(((S,Z)-1-(((S,Z)-1-(((S)-1-((S)-2-((1Z,3S,4Z,6S,7Z,9S,10Z,13Z,15S, |
分子式 | C138H224N42O41 |
分子量 | 3127.51 |
溶解度 | Soluble to 1 mg/ml in sterile water |
储存条件 | -20°C, protect from light |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice |
产品描述:
Rat CGRP-(8-37) (VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF) is a highly selective CGRP receptor antagonist.
CGRP-(8-37) is a truncated version of calcitonin gene-related peptide (CGRP) that binds to the CGRP receptor with similar affinity but does not activate the receptor[1].
CGRP-(8-37) is effective in alleviating mechanical and thermal allodynia in a dose-dependent manner. The 50 nM dose is most efficacious for both forelimb and hindlimb responses. The period of efficacy is 10 min to onset for a duration of 20 min. Post-drug washout responses are not statistically significant compared to pre-drug responses[1]. Intrathecal administration of 5 nmol or 10 nmol of CGRP-(8-37), but not 1 nmol, induces a significant increase in hindpaw withdrawal latency. Intrathecal administration of CGRP-(8-37) not only reverses the SP-induced decrease in latency to both withdrawal responses but also mediates a significant increase in response latency compared to basal levels[2].
特别提醒:
1. 本产品仅供科研使用。请勿用于医药、临床诊断或治疗,食品及化妆品等用途。请勿存放于普通住宅区。
2. 为了您的安全和健康,请穿好实验服并佩戴一次性手套和口罩操作。
联系人:高小姐
手 机:13585831301
Q Q:3004967995
座 机:021-59541103
传 真:021-60443211
地 址:上海嘉定区嘉罗公路1661